Prediction Case File
YouTubeTracking Live

American Express Stock Is Undervalued! Here's Why:

1 extracted signal · 0 resolved · 1 still active

The Patient Investor profile imageThe Patient InvestorIndependent analyst profile
Source published
26 Oct 2026, 18:48 UTC
Recorded by Tahlil Plus
26 Oct 2026, 19:25 UTC
Video preview for American Express Stock Is Undervalued! Here's Why:
Source overview

AI-generated source summary

American Express (AXP) is currently trading at $313.22, exhibiting a recent bearish trend. However, fundamental analysis reveals strong underlying positive factors that suggest a potential bullish outlook. Despite a recent stock decline of 15.97% year-to-date, the company has demonstrated consistent growth in average fee per card, increasing from $61 in late 2019 to $156 recently. This indicates robust pricing power. Furthermore, the company has shown strong earnings growth, with Q3'26 reporting a 28% YoY increase in net income and a 31% increase in diluted EPS. The company has also updated its 2026 guidance, showing increased revenue growth expectations and adjusted EPS projections. While competition is increasing and expenses are rising faster than revenue, particularly in card member services and marketing, American Express's financial health remains strong with significant capital return to shareholders through dividends and share repurchases. The stock is trading at a forward P/E of approximately 16.2, which is considered cheap relative to its historical valuation and growth prospects. A target of $350 is projected, with a failure bound set at $280, which would invalidate the bullish thesis. The sustained increase in dividend yield and strong share buyback program also support a positive long-term outlook for AXP.

AI-generated summary based on the source content.

Live evaluation

Signal outcomes at a glance

Tracking Live
Signals
1
Extracted from this source
Open
1
Still being tracked
Successful
0
Resolved successfully
Failed
0
Resolved unsuccessfully
Other
0
Cancelled, invalid or excluded
Resolved success
—
0 resolved; open signals omitted
Extracted intelligence

Signals in this source

Case timeline

Evidence and evaluation progress

  1. Original source published

    The analyst published the original source item.

  2. Source recorded by Tahlil Plus

    The public source was preserved as the evidence record for this case.

  3. Market predictions extracted

    1 eligible signal linked to this case.

  4. Outcome tracking started

    Tahlil Plus began monitoring the extracted predictions.

  5. Source processing completed

    Source analysis and structured extraction completed.

  6. Live evaluation in progress

    1 signal remains active.

Analyst snapshot

The Patient Investor

Platform-wide history, separate from this source evaluation.

Reliability
47.9
Tracked signals
360
Historical success
34.9%
View full analyst profile →
Methodology & disclosure

Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.

Continue the evidence trail